Literature DB >> 28832211

Ischemic Hand Complications From Intra-Arterial Injection of Sublingual Buprenorphine/Naloxone Among Patients With Opioid Dependency.

Ryan M Wilson1, Shady Elmaraghi1, Brian D Rinker1.   

Abstract

BACKGROUND: Sublingual buprenorphine/naloxone, a common treatment for opioid dependence, is frequently abused by intravenous injection. Inadvertent intra-arterial injection of buprenorphine/naloxone can produce acute ischemic insult to the hand due to gelatin embolism. Our purpose was to review a series of these patients in order to describe the clinical entity, review the outcomes, and propose a rational treatment algorithm.
METHODS: Clinical records of all patients evaluated by the hand surgery team between 2011 and 2015 for ischemia of the hand after buprenorphine/naloxone injection were reviewed. Treatment, complications, and amount of tissue loss were recorded. Patients presenting within 48 hours of the injection were treated with intravenous heparin for 5 days, followed by oral aspirin and clopidogrel for 30 days. Those presenting after 48 hours were treated with aspirin and clopidogrel only.
RESULTS: Ten patients presented during the review period. Average follow-up time was 13 weeks. Eight had ischemia of the radial side of the hand, 1 of the ulnar side, and 1 had bilateral ischemia. Three patients were treated with intravenous heparin and 5 with oral agents. Two presented with dry gangrene and did not receive anticoagulation. All patients experienced tissue loss. There was no difference in outcome regardless of treatment.
CONCLUSIONS: With the increasing use of sublingual buprenorphine/naloxone in opioid dependency, ischemic hand injuries will be seen with greater frequency. Whereas outcomes did not vary with treatment modality in this series, further study is needed to determine the most effective treatment of these injuries.

Entities:  

Keywords:  Suboxone; arterial injection; buprenorphine; drug injection; drug use; gangrene; hand; injection injury; ischemia; opioid abuse

Mesh:

Substances:

Year:  2016        PMID: 28832211      PMCID: PMC5684922          DOI: 10.1177/1558944716672198

Source DB:  PubMed          Journal:  Hand (N Y)        ISSN: 1558-9447


  12 in total

1.  Abuse and diversion of buprenorphine sublingual tablets and film.

Authors:  Eric J Lavonas; S Geoffrey Severtson; Erin M Martinez; Becki Bucher-Bartelson; Marie-Claire Le Lait; Jody L Green; Lenn E Murrelle; Theodore J Cicero; Steven P Kurtz; Andrew Rosenblum; Hilary L Surratt; Richard C Dart
Journal:  J Subst Abuse Treat       Date:  2014-03-03

Review 2.  Complications after unintentional intra-arterial injection of drugs: risks, outcomes, and management strategies.

Authors:  Surjya Sen; Eduardo Nunes Chini; Michael J Brown
Journal:  Mayo Clin Proc       Date:  2005-06       Impact factor: 7.616

Review 3.  Acute hand ischemia after unintentional intraarterial injection of drugs: is catheter-directed thrombolysis useful?

Authors:  Romain Breguet; Sylvain Terraz; Marc Righini; Dominique Didier
Journal:  J Vasc Interv Radiol       Date:  2014-06       Impact factor: 3.464

4.  Injecting buprenorphine-naloxone film: Findings from an explorative qualitative study.

Authors:  Nancy White; Ian Flaherty; Peter Higgs; Briony Larance; Suzanne Nielsen; Louisa Degenhardt; Robert Ali; Nicholas Lintzeris
Journal:  Drug Alcohol Rev       Date:  2015-07-14

5.  Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.

Authors:  Briony Larance; Louisa Degenhardt; Nick Lintzeris; James Bell; Adam Winstock; Paul Dietze; Richard Mattick; Robert Ali; Danielle Horyniak
Journal:  Drug Alcohol Depend       Date:  2011-05-12       Impact factor: 4.492

6.  Acute hand ischemia secondary to intraarterial buprenorphine injection: treatment with iloprost and dextran-40--a case report.

Authors:  P Gouny; J P Gaitz; M Vayssairat
Journal:  Angiology       Date:  1999-07       Impact factor: 3.619

Review 7.  Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.

Authors:  Michael A Yokell; Nickolas D Zaller; Traci C Green; Josiah D Rich
Journal:  Curr Drug Abuse Rev       Date:  2011-03

8.  Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.

Authors:  Sandra D Comer; Maria A Sullivan; Suzanne K Vosburg; Jeanne Manubay; Leslie Amass; Ziva D Cooper; Phillip Saccone; Herbert D Kleber
Journal:  Addiction       Date:  2010-04       Impact factor: 6.526

Review 9.  Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.

Authors:  Jennifer S Orman; Gillian M Keating
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 10.  A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.

Authors:  Michelle R Lofwall; Sharon L Walsh
Journal:  J Addict Med       Date:  2014 Sep-Oct       Impact factor: 3.702

View more
  2 in total

Review 1.  Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review.

Authors:  Nikki Bozinoff; Vitor Tardelli; Dafna Sara Rubin-Kahana; Bernard Le Foll
Journal:  Harm Reduct J       Date:  2022-10-13

Review 2.  Soft Tissue, Bone, and Joint Infections in People Who Inject Drugs.

Authors:  Carlos S Saldana; Darshali A Vyas; Alysse G Wurcel
Journal:  Infect Dis Clin North Am       Date:  2020-09       Impact factor: 5.982

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.